ArticleEuropean journal of medical research2026
Downregulation of USP39 in sepsis reflects immune dysfunction and offers diagnostic and prognostic value.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiomyocyte-enriched OTUD5 alleviates septic cardiomyopathy by promoting NLRP3 deubiquitination and inhibiting NLRP3 inflammasome activation.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUSP39 is involved in mRNA splicing and stress responses. This study analyzed USP39 expression and its clinical relevance in sepsis, aiming to provide a novel treatment target for sepsis.
methodsThe RNA-seq datasets were used for analyzing the expression profile and clinical significance of USP39 in both sepsis and control groups. Functional pathway enrichment was performed using GSEA and GSVA with the clusterProfiler package (3.14.3). Immune infiltration was evaluated via single-sample GSEA (ssGSEA). The prognostic value of USP39 was assessed utilizing Cox regression, and its diagnostic performance was determined via receiver operating characteristic (ROC) curve analysis employing the survival (3.5.7) and pROC (1.18.5) packages, respectively. For single-cell RNA-seq (scRNA-seq) data (GSE175453), we performed quality control, normalization, principal component analysis (PCA), batch correction, clustering, and Uniform Manifold Approximation and Projection (UMAP) visualization employing the Seurat 4.4.0 package. THP-1 cells were treated with lipopolysaccharide (LPS) to mimic septic injury. USP39 was overexpressed via pcDNA3.1 transfection. Cellular assays were conducted to measure cell viability, apoptosis, and inflammatory cytokines (IL-1β, IL-6, TNF-α).
resultsOur study found that USP39 was significantly downregulated in sepsis patients and was associated with age, diabetes, and Intensive Care Unit (ICU)-acquired infections. Functional enrichment analysis revealed that high USP39 expression was linked to metabolic processes, primary immunodeficiency, and spliceosome, and immune response and inflammation pathway. In addition, USP39 also exhibited a high diagnostic value and was identified as an independent prognostic marker in sepsis. ssGSEA revealed higher infiltration of CD8
conclusionThe significant downregulation of USP39 was correlated with both clinical features and immune infiltration in sepsis, highlighting its role in immune regulation and its potential as a prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.